162 related articles for article (PubMed ID: 16220555)
21. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
Komai Y; Saito K; Sakai K; Morimoto S
BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
[TBL] [Abstract][Full Text] [Related]
22. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
[TBL] [Abstract][Full Text] [Related]
23. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.
Takahashi Y; Childs RW
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6353S-9S. PubMed ID: 15448030
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
Ramsey S; Lamb GW; Aitchison M; Graham J; McMillan DC
Cancer; 2007 Jan; 109(2):205-12. PubMed ID: 17149754
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.
Vogl UM; Zehetgruber H; Dominkus M; Hejna M; Zielinski CC; Haitel A; Schmidinger M
Br J Cancer; 2006 Sep; 95(6):691-8. PubMed ID: 16940978
[TBL] [Abstract][Full Text] [Related]
26. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
[TBL] [Abstract][Full Text] [Related]
27. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
Motzer RJ; Mazumdar M; Bacik J; Berg W; Amsterdam A; Ferrara J
J Clin Oncol; 1999 Aug; 17(8):2530-40. PubMed ID: 10561319
[TBL] [Abstract][Full Text] [Related]
28. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
Suppiah R; Shaheen PE; Elson P; Misbah SA; Wood L; Motzer RJ; Negrier S; Andresen SW; Bukowski RM
Cancer; 2006 Oct; 107(8):1793-800. PubMed ID: 16983701
[TBL] [Abstract][Full Text] [Related]
29. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
[TBL] [Abstract][Full Text] [Related]
30. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
31. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone.
Toyoda Y; Shinohara N; Harabayashi T; Abe T; Akino T; Sazawa A; Nonomura K
Eur Urol; 2007 Jul; 52(1):163-8. PubMed ID: 17098353
[TBL] [Abstract][Full Text] [Related]
32. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
33. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma.
Ito K; Asano T; Yoshii H; Satoh A; Sumitomo M; Hayakawa M
Int J Urol; 2006 Nov; 13(11):1365-70. PubMed ID: 17083384
[TBL] [Abstract][Full Text] [Related]
34. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome.
Ficarra V; Novara G; Iafrate M; Cappellaro L; Bratti E; Zattoni F; Artibani W
Eur Urol; 2007 Mar; 51(3):722-9; discussion 729-31. PubMed ID: 16904819
[TBL] [Abstract][Full Text] [Related]
35. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients.
Ficarra V; Galfano A; Guillé F; Schips L; Tostain J; Mejean A; Lang H; Mulders P; De La Taille A; Chautard D; Descotes JL; Cindolo L; Novara G; Rioux-Leclercq N; Zattoni F; Artibani W; Patard JJ
J Urol; 2007 Aug; 178(2):418-24; discussion 423-4. PubMed ID: 17561128
[TBL] [Abstract][Full Text] [Related]
36. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
37. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
Kim HL; Seligson D; Liu X; Janzen N; Bui MH; Yu H; Shi T; Belldegrun AS; Horvath S; Figlin RA
J Urol; 2005 May; 173(5):1496-501. PubMed ID: 15821467
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors of renal cell carcinoma with extension into inferior vena cava.
Tanaka M; Fujimoto K; Okajima E; Tanaka N; Yoshida K; Hirao Y
Int J Urol; 2008 May; 15(5):394-8. PubMed ID: 18452454
[TBL] [Abstract][Full Text] [Related]
39. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
